Abduction Based Drug Target Discovery Using Boolean Control Network

A major challenge in cancer research is to determine the genetic mutations causing the cancerous phenotype of cells and conversely, the actions of drugs initiating programmed cell death in cancer cells. However, such a challenge is compounded by the complexity of the genotype-phenotype relationship and therefore, requires to relate the molecular effects of mutations and drugs to their consequences on cellular phenotypes. Discovering these complex relationships is at the root of new molecular drug targets discovery and cancer etiology investigation. In their elucidation, computational methods play a major role for the inference of the molecular causal actions from molecular and biological networks data analysis. In this article, we propose a theoretical framework where mutations and drug actions are seen as topological perturbations/actions on molecular networks inducing cell phenotype reprogramming. The framework is based on Boolean control networks where the topological network actions are modelled by control parameters. We present a new algorithm using abductive reasoning principles inferring the minimal causal topological actions leading to an expected behavior at stable state. The framework is validated on a model of network regulating the proliferation/apoptosis switch in breast cancer by automatically discovering driver genes and finding drug targets.

[1]  Ruth Nussinov,et al.  Structure and dynamics of molecular networks: A novel paradigm of drug discovery. A comprehensive review , 2012, Pharmacology & therapeutics.

[2]  R. Berro,et al.  Functional consequences of cyclin D1/BRCA1 interaction in breast cancer cells , 2007, Oncogene.

[3]  Neelu Puri,et al.  Mechanism of Resistance and Novel Targets Mediating Resistance to EGFR and c-Met Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer , 2015, PloS one.

[4]  Kyoung-Mee Kim,et al.  The Impact of Concomitant Genomic Alterations on Treatment Outcome for Trastuzumab Therapy in HER2-Positive Gastric Cancer , 2015, Scientific Reports.

[5]  K. Strimbu,et al.  What are biomarkers? , 2010, Current opinion in HIV and AIDS.

[6]  U. Moll,et al.  The MDM2-p53 interaction. , 2003, Molecular cancer research : MCR.

[7]  M. Vidal,et al.  Edgetic perturbation models of human inherited disorders , 2009, Molecular systems biology.

[8]  Filippos Koinis,et al.  Evaluation of proliferation and apoptosis markers in circulating tumor cells of women with early breast cancer who are candidates for tumor dormancy , 2014, Breast Cancer Research.

[9]  W. Quine On Cores and Prime Implicants of Truth Functions , 1959 .

[10]  Alan Veliz-Cuba,et al.  Identification of control targets in Boolean molecular network models via computational algebra , 2015, BMC Systems Biology.

[11]  K. White,et al.  Widespread genetic epistasis among cancer genes , 2014, Nature Communications.

[12]  P. Phillips Epistasis — the essential role of gene interactions in the structure and evolution of genetic systems , 2008, Nature Reviews Genetics.

[13]  W. Foulkes,et al.  BRCA1 and BRCA2: 1994 and beyond , 2004, Nature Reviews Cancer.

[14]  Alan Ashworth,et al.  Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy , 2005, Nature.

[15]  Livia Perfetto,et al.  SIGNOR: a database of causal relationships between biological entities , 2015, Nucleic Acids Res..

[16]  Z. Yao,et al.  DNA-independent PARP-1 activation by phosphorylated ERK2 increases Elk1 activity: a link to histone acetylation. , 2007, Molecular cell.

[17]  Sudhir Gupta,et al.  Molecular signaling in death receptor and mitochondrial pathways of apoptosis (Review). , 2003, International journal of oncology.

[18]  Ana Lluch,et al.  Molecular biology in breast cancer: intrinsic subtypes and signaling pathways. , 2012, Cancer treatment reviews.

[19]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[20]  Larry Rubinstein,et al.  Poly(ADP-ribose) polymerase inhibition enhances p53-dependent and -independent DNA damage responses induced by DNA damaging agent , 2011, Cell cycle.

[21]  Hui Tian,et al.  BRCA1 physically associates with p53 and stimulates its transcriptional activity , 1998, Oncogene.

[22]  Huitu Liu,et al.  MAPK signal pathways in the regulation of cell proliferation in mammalian cells , 2002, Cell Research.

[23]  J. Garber,et al.  PARP inhibitors in the management of breast cancer: current data and future prospects , 2015, BMC Medicine.

[24]  G. Yarrington Molecular Cell Biology , 1987, The Yale Journal of Biology and Medicine.

[25]  Pierre Marquis,et al.  Extending abduction from propositional to first-order logic , 1991, FAIR.

[26]  C. Deng,et al.  BRCA1: cell cycle checkpoint, genetic instability, DNA damage response and cancer evolution , 2006, Nucleic acids research.

[27]  Dan Li,et al.  BRCA1 regulation of epidermal growth factor receptor (EGFR) expression in human breast cancer cells involves microRNA-146a and is critical for its tumor suppressor function , 2014, Oncogene.

[28]  M. Vidal A unifying view of 21st century systems biology , 2009, FEBS letters.

[29]  S. Khatri,et al.  Application of Max-SAT-based ATPG to optimal cancer therapy design , 2012, BMC Genomics.

[30]  Chad J. Miller,et al.  Kinome-wide Decoding of Network-Attacking Mutations Rewiring Cancer Signaling , 2015, Cell.

[31]  Minoru Kanehisa,et al.  KEGG: new perspectives on genomes, pathways, diseases and drugs , 2016, Nucleic Acids Res..

[32]  Clara Pizzuti Computing prime implicants by integer programming , 1996, Proceedings Eighth IEEE International Conference on Tools with Artificial Intelligence.

[33]  Franck Delaplace,et al.  Abductive Network Action Inference for Targeted Therapy Discovery , 2018, SASB.

[34]  B. Kholodenko,et al.  The dynamic control of signal transduction networks in cancer cells , 2015, Nature Reviews Cancer.

[35]  Fuminori Tsuruta,et al.  The Phosphatidylinositol 3-Kinase (PI3K)-Akt Pathway Suppresses Bax Translocation to Mitochondria* , 2002, The Journal of Biological Chemistry.

[36]  C. Peirce,et al.  Five Hundred and Eighty-First Meeting. April 9, 1867. Monthly Meeting; On the Natural Classification of Arguments , 1865 .

[37]  L. Cantley,et al.  New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[38]  Andrea Ciliberto,et al.  Steady States and Oscillations in the p53/Mdm2 Network , 2005, Cell cycle.

[39]  Tak W. Mak,et al.  Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis , 2006, Nature Reviews Cancer.

[40]  W. Kaelin The Concept of Synthetic Lethality in the Context of Anticancer Therapy , 2005, Nature Reviews Cancer.

[41]  L. Mayo,et al.  The PTEN, Mdm2, p53 tumor suppressor-oncoprotein network. , 2002, Trends in biochemical sciences.

[42]  P. Rothberg,et al.  Oncogenes and cancer. , 1983, Cancer investigation.

[43]  Benjamin J. Raphael,et al.  Mutational landscape and significance across 12 major cancer types , 2013, Nature.

[44]  M. Pagano,et al.  Cyclin D1 is a nuclear protein required for cell cycle progression in G1. , 1993, Genes & development.

[45]  J. McCubrey,et al.  Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapy , 2003, Leukemia.

[46]  M. Malanga,et al.  Poly(ADP-ribose) Binds to Specific Domains of p53 and Alters Its DNA Binding Functions* , 1998, The Journal of Biological Chemistry.

[47]  P. Mullan,et al.  The role of BRCA1 in transcriptional regulation and cell cycle control , 2006, Oncogene.

[48]  M. Barančík,et al.  Mitogen-activated protein kinases and their role in regulation of cellular processes. , 2002, General physiology and biophysics.

[49]  J. Alao,et al.  Molecular Cancer BioMed Central Review The regulation of cyclin D1 degradation: roles in cancer development and the potential for therapeutic invention , 2007 .

[50]  Tim Beißbarth,et al.  Boolean ErbB network reconstructions and perturbation simulations reveal individual drug response in different breast cancer cell lines , 2014, BMC Systems Biology.

[51]  R. Price,et al.  Artemether-lumefantrine treatment of uncomplicated Plasmodium falciparum malaria: a systematic review and meta-analysis of day 7 lumefantrine concentrations and therapeutic response using individual patient data , 2015, BMC Medicine.

[52]  Réka Albert,et al.  Cell Fate Reprogramming by Control of Intracellular Network Dynamics , 2014, PLoS Comput. Biol..

[53]  Hai Hu,et al.  Loss of BRCA1 leads to an increase in epidermal growth factor receptor expression in mammary epithelial cells, and epidermal growth factor receptor inhibition prevents estrogen receptor-negative cancers in BRCA1-mutant mice , 2011, Breast Cancer Research.

[54]  T. Mak,et al.  Regulation of PTEN transcription by p53. , 2001, Molecular cell.

[55]  A. Barabasi,et al.  Interactome Networks and Human Disease , 2011, Cell.

[56]  Akif Uzman,et al.  Molecular Cell Biology (4th edition): Harvey Lodish, Arnold Berk, S. Lawrence Zipursky, Paul Matsudaira, David Baltimore and James Darnell; Freeman & Co., New York, NY, 2000, 1084 pp., list price $102.25, ISBN 0-7167-3136-3 , 2001 .

[57]  Aniruddha Datta,et al.  Systems biology Advance Access publication December 30, 2010 Cancer therapy design based on pathway logic , 2022 .

[58]  K. Kinzler,et al.  Cancer Genome Landscapes , 2013, Science.

[59]  John Calvin Reed,et al.  Tumor suppressor p53 is a direct transcriptional activator of the human bax gene , 1995, Cell.